Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Joshua Haimi"'
Autor:
Abdallah Amireh, Sean Scarpiello, Farah Fourcand, Joshua Haimi, Sokutay Bozkurt, Sindhu Sindhu, Navid Tabibzadeh, Nancy Gadallah, Siddhart Mehta, Jawad F Kirmani
Publikováno v:
Stroke: Vascular and Interventional Neurology, Vol 3, Iss S1 (2023)
Introduction Cortical venous thrombosis is a rare and underrepresented etiology for atypical cortical intracerebral hemorrhages (ICH). Cortical venous thrombosis poses a diagnostic challenge compared to dural venous sinus thrombosis. Venogram studies
Externí odkaz:
https://doaj.org/article/0b107e0188dd459aa2f615cae48dc485
Autor:
Farah Y Fourcand, Sindhu Sahito, Ch Hassan Ali, Elahe Marandi, Joshua Haimi, Ilya Dubinsky, Yong‐Bum Song, Siddhart Mehta, Navid Tabibzadeh, Nancy Gadallah, Spozhmy Panezai, Jawad F Kirmani
Publikováno v:
Stroke: Vascular and Interventional Neurology, Vol 3, Iss S1 (2023)
Introduction Intravenous tenecteplase (TNK) is currently being used as a thrombolytic agent in acute ischemic stroke (AIS) and has has been shown to be non‐inferior to intravenous alteplase according to recent studies. Intracranial hemorrhage (ICH)
Externí odkaz:
https://doaj.org/article/d459c51ef9ee45b4bde0d49b7b7eba37
Autor:
Farah Fourcand, Sindhu Sahito, ChHassan Ali, Elahe Marandi, Joshua Haimi, Ilya Dubinsky, Yong-Bum Song, Siddhart Mehta, Navid Tabibzadeh, Nancy E Gadallah, Spozhmy Panezai, Jawad F Kirmani
Publikováno v:
Stroke. 54
Background: Intravenous tenecteplase (TNK) is currently being used as a thrombolytic agent in acute ischemic stroke (AIS) and has has been shown to be non-inferior to intravenous alteplase according to recent studies. Intracranial hemorrhage (ICH) as
Autor:
Thomas Snyder, Joshua Haimi, Farah Fourcand, Ch Hassan Ali, Ilya Dubinski, Yenna Le, Nancy E Gadallah, Haralabos Zacharatos, Siddhart Mehta, Jawad F Kirmani
Publikováno v:
Stroke. 54
Introduction: The goal of this study was to evaluate recanalization rates, incidence of hemorrhagic transformation, and clinical outcomes in patients with medium vessel occlusion (MVO) strokes receiving tenecteplase (TNK) and endovascular treatment (